It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Micro RNAs (miRNAs, miRs) and relevant networks might exert crucial functions during differential host cell infection by the different Leishmania species. Thus, a bioinformatic analysis of microarray datasets was developed to identify pivotal shared biomarkers and miRNA-based regulatory networks for Leishmaniasis. A transcriptomic analysis by employing a comprehensive set of gene expression profiling microarrays was conducted to identify the key genes and miRNAs relevant for Leishmania spp. infections. Accordingly, the gene expression profiles of healthy human controls were compared with those of individuals infected with Leishmania mexicana, L. major, L. donovani, and L. braziliensis. The enrichment analysis for datasets was conducted by utilizing EnrichR database, and Protein–Protein Interaction (PPI) network to identify the hub genes. The prognostic value of hub genes was assessed by using receiver operating characteristic (ROC) curves. Finally, the miRNAs that interact with the hub genes were identified using miRTarBase, miRWalk, TargetScan, and miRNet. Differentially expressed genes were identified between the groups compared in this study. These genes were significantly enriched in inflammatory responses, cytokine-mediated signaling pathways and granulocyte and neutrophil chemotaxis responses. The identification of hub genes of recruited datasets suggested that TNF, SOCS3, JUN, TNFAIP3, and CXCL9 may serve as potential infection biomarkers and could deserve value as prognostic biomarkers for leishmaniasis. Additionally, inferred data from miRWalk revealed a significant degree of interaction of a number of miRNAs (hsa-miR-8085, hsa-miR-4673, hsa-miR-4743-3p, hsa-miR-892c-3p, hsa-miR-4644, hsa-miR-671-5p, hsa-miR-7106-5p, hsa-miR-4267, hsa-miR-5196-5p, and hsa-miR-4252) with the majority of the hub genes, suggesting such miRNAs play a crucial role afterwards parasite infection. The hub genes and hub miRNAs identified in this study could be potentially suggested as therapeutic targets or biomarkers for the management of leishmaniasis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Shiraz University of Medical Sciences, Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698); Shiraz University of Medical Sciences, Infertility Research Center, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)
2 Shiraz University of Medical Sciences, Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698); Shiraz University of Medical Sciences, Epilepsy Research Center, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)
3 Shiraz University of Medical Sciences, Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698); Shiraz University of Medical Sciences, Student Research Committee, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)
4 Shiraz University of Medical Sciences, Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz, Iran (GRID:grid.412571.4) (ISNI:0000 0000 8819 4698)
5 Medical University of Innsbruck, Department of Medical Genetics, Innsbruck, Austria (GRID:grid.5361.1) (ISNI:0000 0000 8853 2677)
6 Khomein University of Medical Sciences, Molecular and Medicine Research Center, Khomein, Iran (GRID:grid.411746.1) (ISNI:0000 0004 4911 7066); Khomein University of Medical Sciences, Department of Medical Laboratory Sciences, Khomein, Iran (GRID:grid.411746.1) (ISNI:0000 0004 4911 7066)
7 University of Salamanca, Infectious and Tropical Diseases Group (E-INTRO), Faculty of Pharmacy, Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817)